Launches of Tuzulby® methylphenidate prolonged-release chewable tablets and Paxneury® guanfacine prolonged-release tablets, also in 5mg, 6mg, and 7mg strengthsTwo differentiated treatments exemplify ...

German CNS-focused specialist Neuraxpharm Group announced the launches in Europe of Tuzulby (methylphenidate hydrochloride) prolonged-release chewable tablets and Paxneury (guanfacine) ...

There are concerns that the drugs are being misused for academic performance. Read more at straitstimes.com. Read more at ...

After evaluating scans of almost 5,800 children with and without attention deficit disorder, US researchers discovered that ...

Prescriptions for methylphenidate, a central nervous system stimulant primarily used to treat attention deficit hyperactivity ...

Children with attention-deficit/hyperactivity disorder who receive methylphenidate may be at an increased risk of having a ...

Attention-deficit/hyperactivity disorder (ADHD) affects 3%–5% of children and about 2.5% of adults, though prevalence varies ...